MAPT and Alzheimer disease: In 2018, the NIA-AA defined AD based on the AT(N) biomarker system, which assessed the presence of Aβ plaques (A), fibrillar Tau (T), and neurodegeneration or neuronal injury (N) to categorize the presence and extent of AD [14].